TrialJournal of hematology & oncology2023

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.

Hua Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.